Gabapentin, an antiepileptic drug, has been used effectively for different types of pain management. This study demonstrates that gabapentin has minimal side effects and is an alternative to opioids and nonsteroidal antiinflammatory drugs for management of the bimodal nature of pain of Guillain-Barré Syndrome patients.
Background: This study aimed to determine whether ultrasound-guided transversus abdominis plane (TAP) block is more effective in reducing postoperative pain and analgesic consumption than local anesthetic infiltration (LAI) at the port site for elective laparoscopic gynecological surgeries.Methods: Eighty patients with the American Society of Anesthesiologists status I/II undergoing laparoscopic gynecology surgery were enrolled for this randomized control trial. After general anesthesia was administered, patients in group C received LAI at each port site, and patients in group T received bilateral ultrasound-guided TAP. Postoperative pain was assessed at time intervals of 1/2, 2, 4, 6, 8, and 24 h using the numeric pain scale (NPS). Clinical metrics such as postoperative analgesic diclofenac consumption, need for rescue fentanyl, nausea-vomiting scores, and antiemetic requirements were also recorded.Results: Seventy-four patients were included in the final analysis. Postoperatively, patients in group T had significantly lower NPS than those in group C (P < 0.05). The highest difference in the postoperative NPS was observed at 2 h (median [1Q, 3Q]; group C = 3 [2, 4]; group T = 1 [0, 2]; P < 0.001). A statistically significant difference was observed in the frequency of diclofenac (75 mg intravenous) requirement between the groups (P = 0.010). No significant difference was observed between the groups in need of rescue fentanyl or antiemetic and the nausea-vomiting scores.Conclusions: In patients undergoing laparoscopic gynecological surgery, ultrasound-guided TAP block provided greater postoperative analgesic benefits in terms of lower NPS and reduced analgesic requirements than port site LAI.
Background:
Only a few studies have evaluated the analgesic effect of erector spinae plane block (ESPB) for laparoscopic cholecystectomy surgery. We aimed to evaluate the analgesic effect of ESPB in patients undergoing laparoscopic cholecystectomy.
Methods:
Seventy-five
patients of American Society of Anaesthesiologists (ASA) grade I/II aged
18-60 years
undergoing elective laparoscopic cholecystectomy were enrolled and were randomly assigned to group C or T. Patients in group C were given general anaesthesia alone, and patients in group T were given bilateral
ultrasound-guided
ESPB followed by general anaesthesia. The primary objective was to compare total 24 hours postoperative analgesic consumption of tramadol, and the secondary objective was to indicate the need for rescue analgesia and numeric pain rating scores (NRSs) at rest and on movement between the groups.
Results:
Sixty-six
patients were included for final analysis. The total tramadol consumption in 24 hours postoperative period for group T was 105.21±60.18 mg and for group C was 178.12±54.3 mg, and the difference was statistically highly significant (
P
= .0001). The need for rescue analgesia (fentanyl) was also statistically significantly lower in group T compared to group C (0.91±5.22 mcg vs 13.64±23.82 mcg,
P
= .002). The postoperative NRS at ½, 2, 4, 6, and 8 hours at rest and on movement was statistically lower in group T than group C, although this difference was not of clinical significance.
Conclusion:
In patients undergoing laparoscopic cholecystectomy, bilateral
ultrasound-guided
ESPB provided effective analgesia as it reduced the total tramadol consumption and the need for rescue analgesia in 24 hours postoperative period.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.